Understand the source comparison
Step 2: Prepare the Scalp Application Site and Determine Subcutaneous vs Topical Route
Scalp preparation affects peptide penetration depth. For topical application: cleanse the target area (crown, hairline, vertex) with alcohol wipes to remove sebum and dead keratinocytes that block dermal absorption. Allow the alcohol to evaporate fully (60–90
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Scalp preparation affects peptide penetration depth. For topical application: cleanse the target area (crown, hairline, vertex) with alcohol wipes to remove sebum and dead keratinocytes that block dermal absorption. Allow the alcohol to evaporate fully (60–90 seconds). Residual alcohol denatures peptides on contact. Apply AHK-Cu solution using a 1mL insulin syringe without the needle, dispensing 0.1–0.2mL per 2cm² section of affected scalp. Massage gently for 30–60 seconds to drive the solution through the stratum corneum into the upper dermis where follicular bulbs reside.
- Subcutaneous injection delivers higher bioavailability (85–95% vs 40–60% topical) but requires sterile technique. Use a 0.5-inch 30-gauge insulin needle. Pinch the scalp skin to create a subcutaneous pocket, insert the needle at a 45-degree angle, and inject 0.1–0.2mL per site. Rotate injection sites across the affected area to prevent fibrosis from repeated trauma. Subcutaneous administration bypasses first-pass metabolism in the epidermis, allowing direct peptide-receptor binding in the dermal papilla.
- Application frequency: 3–5 times weekly. Daily dosing does not improve outcomes. Keratinocyte proliferation follows a circadian rhythm tied to hair follicle cycling, and over-saturation of copper peptide receptors leads to downregulation. The anagen extension effect plateaus at 5 applications per week. Timing relative to other topicals: apply AHK-Cu first, wait 15–20 minutes for absorption, then apply minoxidil or tretinoin if part of your protocol. Minoxidil's propylene glycol carrier can solubilise peptides before dermal penetration, reducing efficacy.